Supporting global health innovation, this comprehensive life sciences construction project delivers cutting-edge laboratory and corporate spaces for Vaxcyte, a next-generation vaccine company.

Spanning Levels 2 through 6, this massive tenant improvement encompasses extensive lab renovations, new laboratory construction, and modern office refreshes. To minimize disruption to Vaxcyte’s critical ongoing research, the project is executed through carefully sequenced phasing from late 2024 through mid-2026.

The expansive scope of work includes full architectural build-outs, complex MEP (mechanical, electrical, and plumbing) upgrades, advanced security and audio-visual integrations, and complete furniture and signage procurement.